ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
A phase 2 trial of ARX788 in HER2-positive breast cancer, run by Ambrx, Inc., active and no longer recruiting.
Overview
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) is a phase 2 interventional study registered as NCT04829604 by Ambrx, Inc., with 72 participants enrolled, started 2021-10-26 and due to reach its primary completion in 2026-12. Interventions recorded: ARX788.
Similar pages
not linked directly; found by shared links- TrialDual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Shares HER2-positive breast cancer and the tag pipeline.
- TrialA Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
Shares HER2-positive breast cancer and the tag pipeline.
- TrialA Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Shares HER2-positive breast cancer and the tag pipeline.
- TrialA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Shares HER2-positive breast cancer and the tag pipeline.
- TrialA Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Shares HER2-positive breast cancer and the tag pipeline.
- TrialClinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
Shares HER2-positive breast cancer and the tag pipeline.
- TrialA Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Shares HER2-positive breast cancer and the tag pipeline.
- TrialTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Shares HER2-positive breast cancer and the tag pipeline.